Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 10 | 2022 | 49 | 1.550 |
Why?
|
| Hemorrhage | 8 | 2021 | 82 | 0.630 |
Why?
|
| Hemophilia B | 4 | 2020 | 11 | 0.470 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2023 | 10 | 0.460 |
Why?
|
| Factor VIII | 7 | 2023 | 32 | 0.410 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 37 | 0.350 |
Why?
|
| Heparin | 2 | 2020 | 22 | 0.340 |
Why?
|
| Hemarthrosis | 3 | 2021 | 22 | 0.330 |
Why?
|
| Anticoagulants | 2 | 2020 | 88 | 0.320 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 1 | 0.300 |
Why?
|
| Factor IX | 2 | 2020 | 7 | 0.300 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 22 | 0.300 |
Why?
|
| Autoantibodies | 3 | 2006 | 82 | 0.290 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 183 | 0.280 |
Why?
|
| von Willebrand Factor | 4 | 2023 | 11 | 0.240 |
Why?
|
| Exercise Therapy | 1 | 2006 | 91 | 0.240 |
Why?
|
| Thrombophilia | 2 | 2020 | 6 | 0.230 |
Why?
|
| Humans | 26 | 2023 | 27174 | 0.230 |
Why?
|
| Hemostasis | 2 | 2016 | 11 | 0.230 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 14 | 0.220 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2004 | 15 | 0.220 |
Why?
|
| Hemostatics | 1 | 2023 | 11 | 0.220 |
Why?
|
| Adult | 13 | 2023 | 7921 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2020 | 30 | 0.200 |
Why?
|
| Sex Chromosome Disorders | 1 | 2022 | 1 | 0.200 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 5 | 0.190 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 10 | 0.190 |
Why?
|
| Adolescent | 7 | 2023 | 2179 | 0.180 |
Why?
|
| Physical Therapists | 1 | 2021 | 5 | 0.180 |
Why?
|
| Young Adult | 7 | 2023 | 2026 | 0.180 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 36 | 0.170 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 4 | 0.170 |
Why?
|
| Serum Albumin | 1 | 2020 | 25 | 0.170 |
Why?
|
| Genetic Variation | 2 | 2017 | 97 | 0.160 |
Why?
|
| Health Literacy | 1 | 2021 | 108 | 0.160 |
Why?
|
| Autoimmune Diseases | 3 | 2006 | 44 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 14 | 0.150 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 12 | 0.150 |
Why?
|
| Factor VIIa | 1 | 2017 | 8 | 0.140 |
Why?
|
| von Willebrand Disease, Type 2 | 1 | 2017 | 1 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2017 | 21 | 0.140 |
Why?
|
| Joint Diseases | 1 | 2018 | 114 | 0.130 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Albumins | 1 | 2016 | 18 | 0.130 |
Why?
|
| Male | 11 | 2023 | 14830 | 0.120 |
Why?
|
| Child | 4 | 2023 | 1260 | 0.120 |
Why?
|
| Blood Coagulation Factors | 2 | 2006 | 20 | 0.120 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2012 | 633 | 0.110 |
Why?
|
| Middle Aged | 8 | 2020 | 9039 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2012 | 803 | 0.110 |
Why?
|
| United States | 4 | 2018 | 2069 | 0.090 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2011 | 1 | 0.090 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Female | 7 | 2023 | 15277 | 0.090 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 56 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 110 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 17 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2008 | 18 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2008 | 44 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 216 | 0.070 |
Why?
|
| Liver | 1 | 2008 | 148 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 30 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 42 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 2336 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 43 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 331 | 0.060 |
Why?
|
| Ankle Joint | 1 | 2006 | 43 | 0.060 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 4 | 0.060 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 7 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 29 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 73 | 0.060 |
Why?
|
| Fever | 1 | 2005 | 34 | 0.060 |
Why?
|
| Phenotype | 2 | 2017 | 312 | 0.060 |
Why?
|
| Pneumonectomy | 1 | 2006 | 77 | 0.060 |
Why?
|
| von Willebrand Diseases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 72 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2016 | 3525 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 3 | 0.060 |
Why?
|
| Trophoblasts | 1 | 2004 | 2 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 140 | 0.060 |
Why?
|
| Elbow Joint | 1 | 2006 | 123 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 347 | 0.060 |
Why?
|
| Quality of Life | 2 | 2020 | 630 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 67 | 0.060 |
Why?
|
| Hemorrhagic Disorders | 1 | 2004 | 1 | 0.060 |
Why?
|
| Paraproteins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Fibrin | 1 | 2004 | 4 | 0.060 |
Why?
|
| Biopolymers | 1 | 2004 | 6 | 0.050 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 121 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 26 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2023 | 5 | 0.050 |
Why?
|
| Plasma | 1 | 2023 | 16 | 0.050 |
Why?
|
| Pregnancy | 2 | 2020 | 331 | 0.050 |
Why?
|
| Apoptosis | 1 | 2004 | 210 | 0.050 |
Why?
|
| Comorbidity | 2 | 2018 | 488 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2023 | 41 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1155 | 0.050 |
Why?
|
| Range of Motion, Articular | 1 | 2006 | 708 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2022 | 10 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2023 | 1802 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2001 | 15 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 87 | 0.050 |
Why?
|
| Elective Surgical Procedures | 2 | 2012 | 37 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2023 | 623 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 1784 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 4834 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 4 | 0.040 |
Why?
|
| Aged | 3 | 2020 | 9094 | 0.040 |
Why?
|
| North America | 1 | 2020 | 39 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 111 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 551 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 52 | 0.040 |
Why?
|
| Knee Joint | 1 | 2006 | 754 | 0.040 |
Why?
|
| Shoulder Joint | 1 | 2006 | 651 | 0.040 |
Why?
|
| Hip Joint | 1 | 2006 | 545 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 415 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 1 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 2 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 9 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2023 | 3546 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2017 | 4 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 104 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2017 | 18 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 55 | 0.030 |
Why?
|
| Homozygote | 1 | 2017 | 20 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 67 | 0.030 |
Why?
|
| Headache | 1 | 2017 | 38 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 67 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 121 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 86 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 126 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 156 | 0.030 |
Why?
|
| Heterozygote | 1 | 2017 | 102 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 24 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 4 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2016 | 12 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 73 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 57 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 589 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 368 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 903 | 0.030 |
Why?
|
| Depression | 1 | 2018 | 446 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 892 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 512 | 0.030 |
Why?
|
| Early Ambulation | 1 | 2011 | 17 | 0.020 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2011 | 7 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 15 | 0.020 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 8 | 0.020 |
Why?
|
| Anesthesia, Epidural | 1 | 2011 | 19 | 0.020 |
Why?
|
| Cell Division | 1 | 2011 | 82 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 46 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 110 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 226 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 261 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 310 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 331 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 433 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 1414 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2006 | 6 | 0.020 |
Why?
|
| Carboplatin | 1 | 2006 | 26 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 17 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 48 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2006 | 51 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2006 | 30 | 0.020 |
Why?
|
| Prednisone | 1 | 2006 | 66 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 928 | 0.010 |
Why?
|
| Bleeding Time | 1 | 2005 | 1 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2005 | 19 | 0.010 |
Why?
|
| Placenta | 1 | 2004 | 7 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 26 | 0.010 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 7 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 30 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 305 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 120 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 92 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 74 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 368 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 185 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 245 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 165 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 524 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 234 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 485 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 3625 | 0.010 |
Why?
|